BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) announced that one of its subsidiaries, DiagnosTear, has signed a services agreement with a pharmaceuticals company to provide analysis services with its TeaRx multi-parameter diagnostic assays for use in an clinical trial for dry eye syndrome (DES).
The agreement marks the first time TeaRx will be used in a drug trial. The TeaRx assays will be used to characterize sub populations of responders and non-responders to the new DES drug treatment.
Assuming the TeaRx analysis differentiates between responders and non-responders, the parties plan to extend their collaboration to a joint-development project of a potential companion diagnostics solution.
In a statement, Suzana Nahum Zilberberg, BioLight’s CEO, said that DES is a multifactorial condition and requires a personalized approach to therapy.
“Indeed, the recent launch of a second FDA-approved drug for the treatment of DES clearly demonstrates that significant unmet medical need remains for the personalized treatment of patients suffering from this condition,” she added.
“With that in mind, we are thrilled to be involved in this clinical trial, and are optimistic about the role that TeaRx may play in the development of the next generation of DES therapeutics,” Ms. Zilberberg said.
